Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sertraline hydrochloride, quantity: 111.92 mg (equivalent: sertraline, qty 100 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; hyprolose; sodium starch glycollate type a; magnesium stearate; calcium hydrogen phosphate dihydrate; titanium dioxide; hypromellose; polysorbate 80; macrogol 400; peg-150 distearate; lauromacrogol 400 - children and adolescents sertraline hydrochloride is indicated for the treatment of children (aged 6 years of age and older) and adolescents with ocd.,adults sertraline hydrochloride is indicated for: the treatment of major depression, obsessive compulsive disorder (ocd) and panic disorder. sertraline hydrochloride is indicated for the treatment of social phobia (social anxiety disorder) and the prevention of its relapse. sertraline hydrochloride is indicated for the treatment of premenstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sertraline hydrochloride, quantity: 55.96 mg (equivalent: sertraline, qty 50 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; hyprolose; sodium starch glycollate type a; magnesium stearate; calcium hydrogen phosphate dihydrate; titanium dioxide; hypromellose; polysorbate 80; macrogol 400; peg-150 distearate; lauromacrogol 400 - children and adolescents sertraline hydrochloride is indicated for the treatment of children (aged 6 years of age and older) and adolescents with ocd.,adults sertraline hydrochloride is indicated for: the treatment of major depression, obsessive compulsive disorder (ocd) and panic disorder. sertraline hydrochloride is indicated for the treatment of social phobia (social anxiety disorder) and the prevention of its relapse. sertraline hydrochloride is indicated for the treatment of premenstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - metoprolol succinate, quantity: 47.501 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; ethylcellulose; sodium stearylfumarate; triethyl citrate; croscarmellose sodium; purified talc; macrogol 6000; silicified microcrystalline cellulose; silicon dioxide; methacrylic acid copolymer; povidone; titanium dioxide; hypromellose; peg-150 distearate; lauromacrogol 400 - stable, chronic heart failure as an adjunct to other heart failure therapy.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - metoprolol succinate, quantity: 190 mg - tablet, modified release - excipient ingredients: povidone; methacrylic acid copolymer; croscarmellose sodium; ethylcellulose; purified talc; sodium stearylfumarate; microcrystalline cellulose; macrogol 6000; triethyl citrate; silicified microcrystalline cellulose; silicon dioxide; titanium dioxide; hypromellose; peg-150 distearate; lauromacrogol 400 - stable, chronic heart failure as an adjunct to other heart failure therapy.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - metoprolol succinate, quantity: 95 mg - tablet, modified release - excipient ingredients: povidone; triethyl citrate; croscarmellose sodium; methacrylic acid copolymer; purified talc; ethylcellulose; microcrystalline cellulose; silicified microcrystalline cellulose; sodium stearylfumarate; silicon dioxide; macrogol 6000; titanium dioxide; hypromellose; peg-150 distearate; lauromacrogol 400 - stable, chronic heart failure as an adjunct to other heart failure therapy.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - metoprolol succinate, quantity: 23.75 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; ethylcellulose; triethyl citrate; silicified microcrystalline cellulose; methacrylic acid copolymer; sodium stearylfumarate; macrogol 6000; povidone; purified talc; croscarmellose sodium; silicon dioxide; titanium dioxide; hypromellose; peg-150 distearate; lauromacrogol 400 - stable, chronic heart failure as an adjunct to other heart failure therapy.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - metoprolol succinate, quantity: 47.501 mg - tablet, modified release - excipient ingredients: triethyl citrate; sodium stearylfumarate; povidone; silicified microcrystalline cellulose; croscarmellose sodium; ethylcellulose; microcrystalline cellulose; purified talc; methacrylic acid copolymer; silicon dioxide; macrogol 6000; titanium dioxide; hypromellose; peg-150 distearate; lauromacrogol 400 - stable, chronic heart failure as an adjunct to other heart failure therapy.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - metoprolol succinate, quantity: 47.5 mg - tablet, modified release - excipient ingredients: silicon dioxide; croscarmellose sodium; methacrylic acid copolymer; povidone; macrogol 6000; microcrystalline cellulose; ethylcellulose; purified talc; silicified microcrystalline cellulose; sodium stearylfumarate; triethyl citrate; titanium dioxide; hypromellose; peg-150 distearate; lauromacrogol 400 - stable, chronic heart failure as an adjunct to other heart failure therapy.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - metoprolol succinate, quantity: 23.75 mg - tablet, modified release - excipient ingredients: macrogol 6000; ethylcellulose; sodium stearylfumarate; silicon dioxide; triethyl citrate; microcrystalline cellulose; purified talc; methacrylic acid copolymer; croscarmellose sodium; povidone; silicified microcrystalline cellulose; titanium dioxide; hypromellose; peg-150 distearate; lauromacrogol 400 - stable, chronic heart failure as an adjunct to other heart failure therapy.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - metoprolol succinate, quantity: 190 mg - tablet, modified release - excipient ingredients: sodium stearylfumarate; silicon dioxide; ethylcellulose; triethyl citrate; methacrylic acid copolymer; povidone; purified talc; macrogol 6000; croscarmellose sodium; silicified microcrystalline cellulose; microcrystalline cellulose; titanium dioxide; hypromellose; peg-150 distearate; lauromacrogol 400 - stable, chronic heart failure as an adjunct to other heart failure therapy.